Table 4.

Treatment-related adverse events (TRAEs)

Adverse events	Any grade, n (%)	Grade 3, n (%)
Increased ALT or AST	16 (36.4%)	1 (2.3%)
Diarrhoea	13 (29.5%)	3 (6.8%)
Post-embolization syndrome (PES)	13 (72.2%)	0
Hand-foot skin reactions	12 (27.3%)	1 (2.3%)
Hypertension	10 (22.7%)	2 (4.5%)
Fatigue	7 (15.9%)	1 (2.3%)
Arthrodynia	3 (6.8%)	0
Decreased appetite	3 (6.8%)	0
Hypothyroidism	3 (6.8%)	0
Oral mucositis	2 (4.5%)	0
Pruritus	2 (4.5%)	0
Nausea	2 (4.5%)	0
Hyperbilirubinemia	1 (2.3%)	1 (2.3%)

ALT alanine aminotransferase, AST aspartate aminotransferase, TRAEs treatment-related adverse events